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Abstracts / Biol Blood Marrow Transplant 19 (2013) S313eS341S340100%), and 100% (range 56-100%) respectively. Cumulative
incidence (CI) of grade II-IV acute GVDHwhile accounting for
competing events, at day +100 was 34.2% (n¼6) and 46.2%
(n¼8) at day +180. The CI for grade III-IV acute GVHD was
22% (n¼4) at day +100, and 29.4% (n¼5) at day +180. CI of
chronic GVHD (cGVHD) was 50.5% at one year. CI of limited
and extensive chronic GVHD was 22.1% (n¼3) and 29.2%
(n¼4), respectively at one year. The CI of relapse was 11.7%
(n¼2) at one year. The non-relapse mortality (NRM) was 0%
at day +100 and 14.7% (n¼2) at one year. Causes of death
include disease relapse (n¼2), GVHD (n¼2), and accident
(n¼1). The overall and progression free survival at one year is
73.5%. Our limited, retrospective data show encouraging
relapse and NRM rates with TLI/ATG-based NMA condi-
tioning, but with higher than previously reported rates of
acute and chronic GVHD, underscoring the need for novel
strategies designed to effectively prevent GVHD.
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Azithromycin Induces the Expansion of Regulatory T Cells
and Diminishes Alloreactive T Cell Proliferation in Vitro
and in Vivo
Sabarinath Venniyil Radhakrishnan 1, Fridrik J. Karlsson 2,
Senthilnathan Palaniyandi 2, Gerhard C. Hildebrandt 2.
1 Internal Medicine, LSUHSC Shreveport, shreveport, LA; 2 Dept.
of Medicine/Feist Weiller Cancer Center, LSUHSC-Shreveport,
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Background: Donor T cell activation in response to alloanti-
gens presented by host antigen presenting cells (APC) is
a critical step in the pathophysiology of Graft Versus Host
Disease. The macrolide Azithromycin (Azi) is studied in lung
transplant and allogeneic hematopoietic cell transplant (HCT)
recipients to decrease graft rejection and progression of lung
injury, respectively.WenowtestedwhetherAzi plays a role in
the modulation of adaptive immune responses by deter-
mining its effects on alloantigen-dependent T cell activation.
Methods: In vitro: Mixed lymphocyte reactions (MLR) using
C57BL/6 (H2b) T cells as responders and B6D2F1 (H2bd) or
BALB/c (H2d) splenocytes as stimulators, as well as TCR
dependent, alloantigen-independent CD3/CD28 or lectin-
type stimulation (Concavalin) assays of C57BL/6 Tcells were
performed in the absence or presence of Azi at varying
concentrations 5mg/ml, 10mg/ml, 20mg/ml, 50mg/ml. T cell
proliferation was assessed by 3HT-uptake. T cells were phe-
notyped and supernatant was tested for cytokine expression.
In vivo: B6D2F1 were pretreated for 2 weeks with Azi at
a dose of 3mg/ml drinking water or received untreated water
as control. Then, animals were conditioned with 12Gy TBI
and transplanted with 4X10E6 bone marrow cells and
6X10E6 splenocytes from allogeneic C57BL/6 donors.Azithromycin (mg/ml)
0 5
MLR cpm 20053  1041 17497  12
IFNg (pg/ml) 590.5  59.9 476.0  42
TNF (pg/ml) 139.1  8.0 114.2  5.
IL-2 (pg/ml) 27.0  0.6 23.4  1.
IL-10 (pg/ml) 115.5  8.8 99.1  14
IL-17 (pg/ml) 24.7  0.9 19.3  3.
IL-4 (pg/ml) d d
IL-6 (pg/ml) 169.3  8.3 139.6  16
%CD4+FOXP3+ 2.5  0.1 2.9  0.
Con A cpm 61791  4529 64350  36
CD3/CD28 cpm 54868  1873 51182  20
cpm ¼ counts per minute
d ¼ below assay sensitivity
* p < 0.05
** P < .01Recipients continued to receive Azi-supplemented or
untreated water, and on day+7, splenic T cell expansion and T
cell phenotyping were done.
Results: AlloreactiveTcell proliferation invitro showedanAzi
dose-dependent decline at 96 hours along with reductions in
TNF, IFNg, IL-2, IL-6, L-10, IL-17. Interestingly, a signiﬁcant
relative expansion of CD4+FOXP3+ T cells (Tregs) within the
CD4+ T cell fraction was observed with increasing Azi-levels
from2.50.1% (0mg/ml) to 5.00.2% (50mg/ml).Nodifferences
in T cell proliferation were seen when T cell stimulation
occurredAPC-independenteither via ConcavalinAor via CD3/
CD28 except for slight suppression at Azi 50 mg/ml. In vivo,
whencompared to controls, pretreatmentwithAzi resulted in
decreased splenic expansion of both CD4+ T cells
(2.1X10E60.2 vs. 4.3X10E60.6, P < .01) and CD8+ T cells
(4.9X10E60.5 vs. 6.4X10E60.4, P < .05) along with a slight
and non-signiﬁcant increase of Tregs (1.5 0.3% vs 1.10.1%).
Conclusion: Azithromycin suppresses alloreactive T cell re-
sponse in vitro and in vivo, paralleled by the induction of Tregs,
supporting its use in lung transplantation and allogeneic HCT.463
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37ns 15340  1157* 12902  1317** 5637  215**
.6 363.6  18.6** 218.7  19.2** 37.05  4.5**
4* 115.4  5.6* 104.6  2.5** 71.3  3.7**
2 23.4  0.2 25.2  1.0 18.3  1.2**
.4 98.9  4.3 65.0  6.8** 19.7  3.5**
3 17.6  1.1 9.4  1.5** 4.2  0.3**
d d d
.3 120.7  11.7* 96.7  9.4** 49.9  5.3**
1 2.7  0.3 4.2  0.2** 5.0  0.1**
92 66065  3174 40012  2016*
71 51351  1447 51659  862 42002  633**
D0
(Mean 
SE)
D7
(Mean 
SE)
D14
(Mean 
SE)
P value
(Day
7-0)
P value
(Day
14-0)
CD3 (k/uL) 309  117 535  103 1306  403 0.034 0.027
CD3/CD8 (K/uL) 94  42 174  33 325  90 0.021 0.029
CD3/CD4 (K/uL) 309  117 404  102 977  310 0.249 0.045
CD16/CD56
(K/uL)
124  60 404  110 496  162 0.029 0.044
CD19 (K/uL) 68  39 89  36 116  31 0.183 0.044
Total Lymphs
(K/uL)
488  167 942  160 2353  532 0.016 0.013
CD11(DC1)
(K/uL)
97.1  60.7 46.3  32.5 32.6  27.5 0.108 0.101
CD123(DC2)
(K/uL)
32.1  7.3 39.7  15.9 45.4  35.8 0.694 0.628
DC1/DC2 2.77  1.26 0.68  0.35 0.61  0.07
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Background: Chronic graft versus host disease (cGVHD) is
associated with mortality, disability and impaired quality of
life. The importance of comorbidities in patients with cGVHD
has not been reported, though this information could be
important for prognostication and tailoring of treatment.
Patients and Methods: We studied 239 patients > 2 years of
age (median 53y, range 11-79) diagnosed with cGVHD by the
NIH consensus criteria and requiring systemic immunosup-
pressive therapy, enrolled in the cGVHDConsortiumat the Fred
HutchinsonCancerResearchCenter (FHCRC).Both incidentand
prevalent cases were included. The Functional Comorbidity
Index (FCI) and the Hematopoietic Cell Transplantation-
speciﬁc Comorbidity Index (HCT-CI) were calculated for all
patients at the time of transplant and cGVHD cohort enroll-
ment. Global cGVHD severity byNIH criteriawasmild or less in
8%, moderate in 54%, and severe in 38% of the patients. Median
follow-up of survivors was 32 months (range 0.6-55.0).
Univariate and multivariate Cox regression models were con-
structed, adjusting for all known and available risk factors
including NIH global severity score at enrollment.
Results: The mean FCI score at the time of transplantation
was 1.8 (range 0-8), increasing to 2.7 (range 0-7) at the time
of cGVHD cohort enrollment (P < .001). The mean HCT-CI
score at the time of transplantation was 2.6 (range 0-8),
increasing to 3.7 (range 0-12) at the time of cohort enroll-
ment (P < .001). Higher FCI scores did not predict risk of
overall or non-relapse mortality. At enrollment, in multi-
variate analyses adjusted for clinical covariates, a statistically
signiﬁcant interaction of the HCT-CI with platelet count was
observed (p¼0.003). Higher HCT-CI scores at enrollment
were associated with an increased risk of overall mortality
when the platelet count was < 100,000/ml (HR 2.01 for 1-pt
increase in HCT-CI: 1.20-3.35, p¼0.01), but not when >
100,000/ml (HR 1.05: 0.90-1.22, p¼0.53). For non-relapse
mortality, higher HCT-CI scores at the time of cGVHD cohort
enrollment were also predictive (HR 1.21:1.04-1.42,P ¼ .01).
Because of overlap between the HCT-CI and the NIH cGVHD
severity scale in the scoring of liver (correlation¼0.61) and
lung (correlation¼0.61) dysfunction, a version of the HCT-CI
that excluded liver and lung variables was tested and
remained signiﬁcantly associated with overall survival in
univariate analysis (HR 1.19,P ¼ .02). Removing the NIH
cGVHD global score from the model did not enhance the
signiﬁcance of the HCT-CI (HR 1.16,P ¼ .02).
Conclusions: A higher comorbidity burden by the HCT-CI at
the time of enrollment into a cGVHD cohort is associated with
an increased risk formortality.We recommend further studies
of comorbidityscoring inpatientswith cGVHDandurge further
investigations that could lead to a mechanistic understanding
of physiologic vulnerability in patients with cGVHD.
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Strategies for treatment of relapse after allogeneic stem cell
transplant (SCT) include withdrawal of immunosuppressivetherapy and donor lymphocyte infusions (DLI). Trials using
cytokines (CK) have alsodemonstrated allo-immune responses
after allogeneic SCT.We evaluated the role of interleukin-2 (IL-
2) and granulocyte-macrophage colony stimulating factor
(GM-CSF) on patients (pts) relapsing after allogeneic SCT.
Twenty three pts (median age¼50, range 7 months to 66
years) received IL-2 at 1 million units/m2 subcutaneously
(days 8-14) without (n¼13) or with (n¼10) GM-CSF at 500
mcg subcutaneously (days 1-14). Pts received a median of 2
cycles (range 1-4) of IL-2/GM-CSF. SCT sources included:
peripheral blood matched-related (n¼9), or unrelated (n¼7),
bone marrow matched related (n¼1), or unrelated (n¼2) or
umbilical cord blood (n¼4) SCT. Diagnosis included AML
(n¼12), MDS (n¼3), ALL (n¼2), non-Hodgkin's lymphoma
(n¼2) and Hodgkin's disease (n¼1), Chronic Lymphocytic
Leukemia (n¼1). Disease status at SCT included CR1¼3, CR2¼
1; all other pts underwent SCT for primary induction failure or
resistant relapse. Median time from SCT to relapse was 5
months. Pts had receivedDLI (n¼13) or chemotherapy (n¼19)
prior to CK therapy. Response rate after CK therapy was 57 %
(13/23, all CR's). Median overall survival (see ﬁgure) after CK
therapy was 9 months (range¼ 1-47 months). Acute or
chronic graft versus host disease occurred in 13 pts after CK
therapy. The table below summarizes analysis of immune
activation. Values represent means +/- standard error at day
0 (ﬁrst day of GM-CSF), day 8 (prior to start of IL-2) and day 14
(last dayof IL-2 andGM-CSF).P-values arebasedonanalysis of
day 7 versus day 0 and day 14 versus day 0, respectively. Flow
cytometric analysis showed an increase in the numbers of T-
lymphocytes (CD3) and T-cell subsets (CD3/CD8 and CD3/
CD4) as well as an increase in natural killer cells (CD16/56).
Although no differenceswere seen in the number of dendritic
cell subsets, DC1/DC2 ratios decreased with the administra-
tion of GM-CSF/IL-2. Limited (n¼ 4) CD4/FoxP3 analysis did
not show change in absolute numbers with administration of
GM-CSF/IL-2 (data not shown).
In conclusion, CK therapy with IL-2  GM-CSF post SCT is
associated with alloimmune responses. Relapse rate remains
high with most pts relapsing after initial responses.
